Clinical impact of genomic analysis in children with B-acute
lymphoblastic leukemia: A pilot study in Slovakia

J 2019

Clinical impact of genomic analysis in children with B-acute lymphoblastic leukemia: A pilot study in Slovakia

VASKA, A., M. MAKOHUSOVA, Karla PLEVOVÁ, K. SKALICKA, M. CERMAK et. al.

Základní údaje

Originální název

Clinical impact of genomic analysis in children with B-acute lymphoblastic leukemia: A pilot study in Slovakia

Autoři

VASKA, A. (703 Slovensko), M. MAKOHUSOVA (703 Slovensko), Karla PLEVOVÁ (203 Česká republika, garant, domácí), K. SKALICKA (703 Slovensko), M. CERMAK (703 Slovensko), F. CHOVANEC (703 Slovensko), O. FABRI (703 Slovensko), P. SVEC (703 Slovensko) a A. KOLENOVA (703 Slovensko)

Vydání

Neoplasma, Bratislava, Slovenská akademie vied, 2019, 0028-2685

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Slovensko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 1.721

Kód RIV

RIV/00216224:14110/19:00112733

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.4149/neo_2019_190328N274

UT WoS

000499649200017

Klíčová slova anglicky

children acute lymphoblastic leukemia; B-other; genetic markers; SNP-array

Štítky

14110212, podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 31. 3. 2020 22:12, Mgr. Pavla Foltynová, Ph.D.

Anotace

V originále

Acute lymphoblastic leukemia (ALL) belongs to a genetically heterogeneous disease associated with a wide range of chromosomal and molecular changes. Determining these changes at the time of diagnosis can help the therapeutic decision, and contributes to the prediction of patients' clinical outcomes. A part of B-ALL (B-other) lacks cytogenetic abnormalities with clinical relevance for prognosis. Our first goal was to retrospectively review genetic results of patients from 2013-2017 and identify number of B-other patients in Slovak population. The second goal was to implement single nucleotide polymorphism (SNP) array analysis to improve the diagnosis and risk stratification. In this study we reviewed 133 B-ALL patients. We found that nearly 40% of them (52 cases) belonged to the B-other ALL group. Eighteen B-other ALL patients were subjected to the analysis using SNP-array. Overall, we identified 126 cytogenomic changes and in 4 patients the SNP array revealed clinically relevant markers of adverse prognosis and high relapse risk. Integrating identified genetic changes into clinical practice can bring improvement of prognosis assessment for children with ALL in Slovakia.

Návaznosti

EF16_013/0001818, projekt VaV

Název: Modernizace a podpora výzkumných aktivit národní infrastruktury pro translační medicínu EATRIS-CZ

Citovat

VASKA, A., M. MAKOHUSOVA, Karla PLEVOVÁ, K. SKALICKA, M. CERMAK, F. CHOVANEC, O. FABRI, P. SVEC a A. KOLENOVA. Clinical impact of genomic analysis in children with B-acute lymphoblastic leukemia: A pilot study in Slovakia. Neoplasma. Bratislava: Slovenská akademie vied, 2019, roč. 66, č. 6, s. 1009-1018. ISSN 0028-2685. Dostupné z: https://dx.doi.org/10.4149/neo_2019_190328N274.

@article{1609499,
   author = {Vaska, A. and Makohusova, M. and Plevová, Karla and Skalicka, K. and Cermak, M. and Chovanec, F. and Fabri, O. and Svec, P. and Kolenova, A.},
   article_location = {Bratislava},
   article_number = {6},
   doi = {http://dx.doi.org/10.4149/neo_2019_190328N274},
   keywords = {children acute lymphoblastic leukemia; B-other; genetic markers; SNP-array},
   language = {eng},
   issn = {0028-2685},
   journal = {Neoplasma},
   title = {Clinical impact of genomic analysis in children with B-acute lymphoblastic leukemia: A pilot study in Slovakia},
   url = {http://dx.doi.org/10.4149/neo_2019_190328N274},
   volume = {66},
   year = {2019}
}

TY  - JOUR
ID  - 1609499
AU  - Vaska, A. - Makohusova, M. - Plevová, Karla - Skalicka, K. - Cermak, M. - Chovanec, F. - Fabri, O. - Svec, P. - Kolenova, A.
PY  - 2019
TI  - Clinical impact of genomic analysis in children with B-acute lymphoblastic leukemia: A pilot study in Slovakia
JF  - Neoplasma
VL  - 66
IS  - 6
SP  - 1009-1018
EP  - 1009-1018
PB  - Slovenská akademie vied
SN  - 00282685
KW  - children acute lymphoblastic leukemia
KW  - B-other
KW  - genetic markers
KW  - SNP-array
UR  - http://dx.doi.org/10.4149/neo_2019_190328N274
L2  - http://dx.doi.org/10.4149/neo_2019_190328N274
N2  - Acute lymphoblastic leukemia (ALL) belongs to a genetically heterogeneous disease associated with a wide range of chromosomal and molecular changes. Determining these changes at the time of diagnosis can help the therapeutic decision, and contributes to the prediction of patients' clinical outcomes. A part of B-ALL (B-other) lacks cytogenetic abnormalities with clinical relevance for prognosis. Our first goal was to retrospectively review genetic results of patients from 2013-2017 and identify number of B-other patients in Slovak population. The second goal was to implement single nucleotide polymorphism (SNP) array analysis to improve the diagnosis and risk stratification. In this study we reviewed 133 B-ALL patients. We found that nearly 40% of them (52 cases) belonged to the B-other ALL group. Eighteen B-other ALL patients were subjected to the analysis using SNP-array. Overall, we identified 126 cytogenomic changes and in 4 patients the SNP array revealed clinically relevant markers of adverse prognosis and high relapse risk. Integrating identified genetic changes into clinical practice can bring improvement of prognosis assessment for children with ALL in Slovakia.
ER  -

VASKA, A., M. MAKOHUSOVA, Karla PLEVOVÁ, K. SKALICKA, M. CERMAK, F. CHOVANEC, O. FABRI, P. SVEC a A. KOLENOVA. Clinical impact of genomic analysis in children with B-acute lymphoblastic leukemia: A pilot study in Slovakia. \textit{Neoplasma}. Bratislava: Slovenská akademie vied, 2019, roč.~66, č.~6, s.~1009-1018. ISSN~0028-2685. Dostupné z: https://dx.doi.org/10.4149/neo\_{}2019\_{}190328N274.

Podrobný výpis o publikaci